The NIFTY MIDCAP 150's movements reflect ongoing market dynamics, with Global Health, JSW Infra, and GlaxoSmithKline ...

ICICI Securities recommended reduce rating on GlaxoSmithKline Pharmaceuticals with a target price of Rs 2,600 in its research ...

The company is working closely with the contract manufacturing facility for resumption of operations. Shares of ...

The "Biopharmaceutical Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034" report has been added to ResearchAndMarkets.com's offering.The Global Biopharmaceutical ...

Amagi is planning to raise Rs 3,200 crore through public listing, and has appointed Kotak Mahindra Capital, Citigroup, IIFL ...

Researchers analyzed long-term survival of women diagnosed with low-risk cervical cancer, from 2010 through 2017, who ...

In the run-up to IPO, media-focussed SaaS unicorn Amagi has appointed Ira Gupta and Giridhar Sanjeevi as independent directors of the company ...

The GOP-led House Judiciary Committee is requesting records from Pfizer’s CEO and an interview with a former company ...

GlaxoSmithKline places its shingles vaccine Shingrix among its top prospects, with peak sales potential of almost $6 billion. Now, Pfizer and BioNTech are joining forces to try to grab a slice of ...

The ten leading companies involved are from the US and Europe: Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson &amp, Johnson, Pfizer ...

Royalty Pharma plc (Nasdaq: RPRX) today announced that it has successfully closed the acquisition of its external manager, RP Management, LLC (“RP Management”). The acquisition received overwhelming ...

Moreover, previous studies have suggested that more conservative options can be successfully used for low-risk, early-stage cervical cancer. The SHAPE trial, for example, showed that simple ...